

Cover Story
Conversation with The Cancer Letter
In an in-depth interview with The Cancer Letter, an FDA official clarified the agency's criteria for approval of drugs that target PD-1 and PD-L1.
Free
By Matthew Bin Han Ong
By Matthew Bin Han Ong
In Brief


Funding Opportunities
Drugs & Targets


Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Hoping to hit a $200M target, NCI and FNIH develop a plan for advancing cancer vaccines
NCI Director Letai: “How aggressive can we be?” - A new working group will conduct site visits and advise NCAB and NCI director on cancer center grants
- Early-onset colorectal cancer demands a new research playbook
- Robert A. Winn named director of Fox Chase Cancer Center
- Letai: “From this point forward, it really is much more like business as usual at the NCI.”













